Zepbound Medicare Part D Coverage: What to Expect in 2026

Why Medicare Part D Usually Does Not Cover Zepbound

Most Medicare Part D plans do not cover Zepbound for weight loss. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) explicitly barred Part D plans from covering drugs used for weight loss, weight gain, or cosmetic purposes. Zepbound's primary FDA-approved indication, chronic weight management, falls squarely within that exclusion. CMS's own guidance confirms this longstanding rule.

The 2003 MMA Exclusion, Explained

Congress passed the exclusion to keep Part D premiums manageable at launch. The statute (42 U.S.C. §1395w-102(e)(2)) lists anti-obesity agents among a handful of drug classes that plans are not required, and are generally not permitted, to cover. The full statutory language is available via the NIH-hosted US Code archive.

Because the exclusion is statutory, CMS cannot waive it by regulation alone. Only an act of Congress can change it, and as of 2026 no such legislation has been enacted, despite the Treat and Reduce Obesity Act (TROA) being reintroduced multiple times.

The Obstructive Sleep Apnea Exception

Zepbound received a second FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. OSA is not a weight-loss indication. That means Part D plans have the option, though not the obligation, to cover Zepbound when it is prescribed specifically for OSA.

A growing minority of Part D formularies added Zepbound for the OSA indication in 2025. Coverage is highly plan-specific. The safest approach is to call the plan's pharmacy benefits number and ask whether tirzepatide appears on the formulary under the ICD-10 code G47.33 (obstructive sleep apnea). Do this before the prescription is written, because a prescription submitted under an uncovered indication will generate an automatic denial.

What "Non-Interference" Means for Your Negotiating Power

Medicare's non-interference clause prevents CMS from negotiating drug prices directly with manufacturers for most drugs. For Zepbound specifically, this means there is no government-negotiated Medicare price to fall back on even if coverage were granted. The Inflation Reduction Act introduced price negotiations for a limited set of drugs, but tirzepatide is not currently on that negotiation list.

What Zepbound Actually Costs Without Coverage

Without insurance, Zepbound carries a cash-pay list price of approximately $1,059 per month. That figure is for the injectable pen at maintenance doses (10 mg, 12.5 mg, or 15 mg weekly). Starter doses (2.5 mg and 5 mg) list slightly lower but most patients reach higher doses within four to eight weeks of titration.

Compounded Tirzepatide as a Lower-Cost Option

FDA-registered 503B outsourcing facilities and, under certain conditions, 503A compounding pharmacies have produced tirzepatide compounded injections. The average compounded price runs around $249 per month, roughly 76% less than the branded list price.

The FDA's position on compounded tirzepatide has shifted. In May 2024 the FDA placed tirzepatide on the shortage list, which temporarily permitted wider compounding. In March 2025, the FDA removed tirzepatide from the shortage list and issued guidance that 503A pharmacies must stop compounding essentially identical copies. FDA's statement on tirzepatide compounding is posted at FDA.gov. The legality and availability of compounded tirzepatide continues to evolve; patients should verify the current regulatory status before purchasing.

GoodRx and Discount Cards

GoodRx and similar discount platforms negotiate prices with pharmacy benefit managers. For Zepbound, GoodRx discounts typically bring the price to $900 to $1,000 per month at major retail chains, which is a modest reduction from list price and well above the compounded alternative. These programs do not work if you are using Medicare; using a discount card while enrolled in Part D can create Part D coordination issues.

Eli Lilly's Zepbound Savings Programs

Eli Lilly runs two main programs to reduce out-of-pocket costs. Eligibility rules differ sharply between them, and neither applies to Medicare beneficiaries in standard ways.

The Zepbound Savings Card (Commercially Insured Patients)

Lilly's savings card allows eligible commercially insured patients to pay as little as $25 per month for Zepbound. The card covers the gap between the patient's copay and a Lilly-set maximum. Eligibility requires:

• Commercial (private) insurance that covers Zepbound
• No federal healthcare program coverage (Medicare, Medicaid, TRICARE, VA, etc.)
• Residence in the United States

Medicare beneficiaries are explicitly excluded. Using the card while on Medicare violates the card's terms and potentially anti-kickback statutes. Lilly's official savings card page is at LillyInsulin.com / Zepbound.

Lilly's Insulin Value Program and Patient Assistance

Lilly runs a separate patient assistance program (PAP) for uninsured or underinsured patients who fall below income thresholds. For Medicare beneficiaries who cannot afford Zepbound and meet income criteria, this program may supply medication at no charge, though tirzepatide for weight management is not always listed among covered products. Patients should contact Lilly Cares (1-800-545-5979) to confirm current product availability under the PAP.

HealthRX Coverage Decision Framework for Medicare Patients Seeking Zepbound:

| Situation | First Step | Realistic Outcome | |---|---|---| | Medicare only, obesity indication | Confirm plan formulary | Almost certainly denied; explore PAP or compounded Tx | | Medicare + OSA diagnosis (G47.33) | Request OSA-specific PA | Coverage possible on select plans | | Medicare + Medicaid (dual eligible) | Check state Medicaid formulary | Varies widely by state | | Commercial insurance | Submit with PA documentation | Approval rates improving; savings card available | | No insurance | Compare 503B compounding pharmacies | Compounded tirzepatide ~$249/month; verify legality |

Prior Authorization: What Every Patient Needs to Know

Even on plans that list Zepbound on their formulary, prior authorization (PA) is nearly universal. The PA process exists to confirm medical necessity before the plan pays.

What Insurers Typically Require for Weight Management

For a weight-loss PA to succeed, most commercial plans require documentation of:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or cardiovascular disease)
• A documented trial of lifestyle intervention (diet and exercise counseling for at least three to six months)
• No contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome)

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% for placebo (P<0.001). That trial, published in the New England Journal of Medicine, is accessible via NEJM.org. Citing this level of clinical evidence in a PA letter strengthens the medical necessity argument.

What Insurers Typically Require for OSA

For Zepbound under the OSA indication, plans generally want:

• Polysomnography or home sleep apnea test confirming moderate-to-severe OSA (AHI ≥15 events/hour)
• Documentation that the patient has obesity (BMI ≥30)
• Prescriber attestation that the drug is intended to treat OSA, not solely weight loss

Appealing a Denial

The appeals process has legally defined timeframes. Under the ACA, urgent appeals must be decided within 72 hours; standard appeals within 30 days for pre-service and 60 days for post-service. If the internal appeal fails, patients can request an Independent Medical Review (IMR) or External Review. The CMS appeals guide walks through each step. Physicians who write detailed letters citing SURMOUNT trial data and the patient's specific comorbidity burden have higher success rates than form letters.

Medicare Advantage Plans: A Different Field

Medicare Advantage (Part C) plans are run by private insurers under CMS contracts. They must cover everything original Medicare covers, but they can add supplemental benefits. A handful of MA plans have added anti-obesity drug coverage as a supplemental benefit, including some tirzepatide access.

How to Check Your MA Plan

Every MA plan publishes a formulary (drug list) annually. The easiest way to check is:

1. Log in to Medicare.gov and use the Plan Finder tool.
2. Search for tirzepatide by name under the drug lookup.
3. Filter results to your zip code and 2026 plan year.

The Medicare Plan Finder is the single most reliable source. Formularies change each year on January 1, so a plan that covered Zepbound in 2025 may not in 2026 and vice versa.

Extra Help / Low Income Subsidy

Medicare's Extra Help program (also called the Low-Income Subsidy, LIS) reduces cost-sharing and premiums for Part D enrollees below certain income thresholds. Extra Help does not expand the list of covered drugs; it only reduces what a patient pays for drugs that are already covered. If Zepbound is not on the formulary, Extra Help does not change that.

The $2,000 Medicare Out-of-Pocket Cap and Its Limits

Starting January 1, 2025, the Inflation Reduction Act capped Medicare Part D out-of-pocket spending at $2,000 per year. This is a meaningful protection for beneficiaries on multiple covered medications. For Zepbound specifically, the cap is largely irrelevant because the drug itself is not covered on most plans. A cap only matters once you clear the deductible and copay phases, and you can only do that on a drug your plan actually covers.

CMS's summary of the $2,000 cap is posted at CMS.gov.

State Medicaid Coverage: Patchwork, but Sometimes Better

Medicaid, unlike Medicare, is not subject to the federal MMA exclusion for anti-obesity drugs. States can choose to cover GLP-1 receptor agonists for obesity, and several have.

As of early 2026:

• Arkansas, California, North Carolina, and a handful of other states added tirzepatide or semaglutide to their Medicaid preferred drug lists for obesity.
• Most states still exclude or heavily restrict GLP-1s due to budget concerns.
• Coverage often requires step therapy (trying a less-expensive agent first, typically orlistat or phentermine/topiramate ER).

The Medicaid.gov Drug Rebate Program database lists which NDCs are covered in each state. Patients on Medicaid or dual Medicare/Medicaid should ask their state's Medicaid pharmacy helpline directly, since formularies update quarterly.

Clinical Context: Why the Coverage Fight Matters

Obesity is a chronic disease affecting more than 42% of U.S. Adults, according to CDC surveillance data. The American Association of Clinical Endocrinologists (AACE) 2016 obesity guidelines, updated in subsequent consensus statements, classify obesity as "a chronic, relapsing, multifactorial, neurobehavioral disease" that warrants long-term pharmacotherapy in appropriate patients. The AACE statement is archived at AACE.com.

In SURMOUNT-2 (N=938), patients with type 2 diabetes and obesity treated with tirzepatide 15 mg lost a mean of 15.7% of body weight at 72 weeks versus 3.3% with placebo. That trial is published in The Lancet. For a Medicare population that skews toward type 2 diabetes and cardiovascular comorbidities, this level of efficacy is directly clinically relevant, yet coverage policy does not yet reflect it.

The American Heart Association's 2023 scientific statement on obesity and cardiovascular risk notes: "Treatment of obesity, including pharmacotherapy, should be considered an integral component of cardiovascular risk reduction." The statement is available at AHA Journals. That framing supports the argument that denying coverage for Zepbound on a cardiovascular risk basis may be short-sighted from a total-cost perspective.

Practical Steps for Medicare Patients in 2026

Getting access to Zepbound on Medicare requires a clear, stepwise approach.

Step 1: Confirm Your Diagnosis Picture

Talk to your prescribing physician about every qualifying diagnosis. If you have documented OSA, that diagnosis opens the door to the OSA formulary pathway. If you have obesity-related cardiovascular disease, type 2 diabetes, or hypertension, those comorbidities strengthen any PA letter regardless of plan type.

Step 2: Run the Medicare Plan Finder

Check Medicare.gov's Plan Finder with tirzepatide entered as the drug. Filter to your county and the 2026 plan year. If even one MA plan in your area covers it, you can compare that plan's total premium and cost-sharing against your current plan during Open Enrollment (October 15 to December 7 each year) or during a Special Enrollment Period.

Step 3: Ask About the OSA Pathway

If you have an OSA diagnosis, ask your physician to write the prescription specifically for OSA under ICD-10 G47.33. Call your plan's pharmacy benefits line before submission. Some pharmacists and even physician offices are unaware that the OSA indication exists; they may default to the obesity diagnosis code, which triggers the automatic exclusion.

Step 4: Contact Lilly Cares for Patient Assistance

For Medicare patients who cannot afford Zepbound at cash price, Lilly Cares (1-800-545-5979) may offer free or reduced-cost product through the PAP. Income documentation (tax returns, Social Security award letters) will be required. Processing can take two to six weeks.

Step 5: Consider Telehealth-Based Access Programs

Several telehealth platforms, including HealthRX, offer physician-supervised weight management programs that can prescribe tirzepatide and coordinate access through compounding pharmacies when branded Zepbound is unaffordable. A physician visit is required before any prescription is issued. Patients should confirm that the prescribing physician is licensed in their state and that the compounding pharmacy holds valid FDA registration.